BIOMARIN PHARMACEUTICAL INC (BMRN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for BMRN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BMRN | Baxalta Inc.; Director | 60 | ["Director, Embecta Corporation","Director, Henry Schein, Inc.(2)","Extensive experience in finance and accounting","Capital markets","Managing large biotechnology and pharmaceutical organizations","Former Executive Vice President, CFO & COO at Baxalta Inc.","Served as Vice President and Chief Financial Officer at Baxter","Held various finance positions at Baxter"] | ["Audit Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| HSIC | Independent Director | 59 | ["Former Executive Vice President, CFO and COO, Baxalta, Inc.","Former Corporate Vice President and CFO, Baxter International, Inc.","Certified Public Accountant (CPA)","Decades of executive and operational experience in the biopharmaceutical and medical device sectors","Key architect of the rationale and strategy to split Baxter International, Inc. and Baxalta, Inc. into two companies","Led multiple M&A and financial transactions common in healthcare","Public Company Board and Governance Experience including serving as Chair of the Audit Committee"] | ["Strategic Advisory Committee"] | 2025 |
| KMX | Audit Committee Member | [] | ["Audit"] | 2022 |
Biography sourced from the proxy statement filing.
Robert J. Hombach joined our Board in September 2017 and currently serves as Chair of the Audit Committee. Mr. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company, until it was acquired by Shire plc, in June 2016. Baxalta was spun off from its parent, Baxter International Inc., a public pharmaceutical company, in July 2015, where Mr. Hombach served as Vice President and Chief Financial Officer from June 2010 until the Baxalta spin-off. Mr. Hombach also served as Treasurer of Baxter from 2007 to 2011 and was Vice President of Finance, Europe, Middle East, and Africa from 2004 to 2007. Prior to this, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the board of Embecta Corporation, a public diabetes company, Henry Schein, Inc. a public company providing healthcare solutions to office-based dental and medical practitioners, and Seaport Therapeutics, Inc., a private biopharmaceutical company. Previously, Mr. Hombach served on the boards of Aptinyx Inc., a public biotechnology company, from May 2018 to June 2023, CarMax, Inc., a public company, from April 2018 to June 2022, and Naurex, Inc., a private pharmaceutical company acquired by Allergan in August 2015. Mr. Hombach holds an M.B.A. from Northwestern University s J.L. Kellogg Graduate School of Management and a B.S. in Finance cum laude from the University of Colorado.